FDA Recall Announcement Related recall of Prazosin: American Health Packaging Recall More about nitrosamine from FDA: Information about Nitrosamine Impurities in Medications Check our website for briefs on additional recent recalls of Atorvastatin, Fasenra, and Gabapentin, and more
In April 2007, the US Food & Drug Administration (FDA) approved the administration of pimobendan only for MVD-affected dogs in heart failure (Stage C), and then in June 2022, the FDA conditionally approved pimobendan to treat MVD-dogs with significantly enlarged left heart chambers (Stage B2)
Furthermore, when we repeated the meta-analysis excluding ELIXA, the trial done with a short-acting GLP-1 receptor agonist in patients with acute coronary syndrome, the outcome of worsening of kidney function, based predominantly on change in eGFR, was also improved. Sattar and colleagues analyzed data from eight randomized, placebo-controlled trials with 60,080 participants testing injectable or oral GLP-1 receptor agonists in adults with type 2 diabetes, including the recently presented AMPLITUDE-O
McFadden 1984
however, results vary greatly from person to person
Residents in Kentucky appreciate this extra support because it makes success easier to sustain